Marker Therapeutics
Pharmaceutical Manufacturing • 
Houston, Texas, United States • 21-50 Employees
Company overview
| Headquarters | 4551 Kennedy Commerce Dr, Houston, Texas 77032, US |
| Phone number | +17134006400 |
| Website | |
| NAICS | 3254 |
| SIC | 873 |
| Keywords | Immunotherapy And T Cell Based Therapies |
| Founded | 2018 |
| Employees | 21-50 |
| Socials |
Key Contacts at Marker Therapeutics
Maria-Bernadette Madel
Director, Corporate Operations And External Communications
Oumar Diouf
Senior Director Of Cmc
Elizabeth Donnelly
Director Of Administration
James Mcquillan
Director Of Accounting
Shelia Sterr
Director Of Hr & Finance
Elizabeth Donnelly
Director Of Administration
Marker Therapeutics Email Formats
Marker Therapeutics uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@markertherapeutics.com), used 76.9% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@markertherapeutics.com | 76.9% |
{first name}{last name} | johndoe@markertherapeutics.com | 15.4% |
{last name}{last name} | doedoe@markertherapeutics.com | 7.7% |
About Marker Therapeutics
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s unique cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens (multiTAA) and kill tumor cells expressing those targets. Once infused into patients, this population of multiTAA-specific T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
Marker Therapeutics revenue & valuation
| Annual revenue | $5,388,071 |
| Revenue per employee | $216,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $17,300,000 |
| Total funding | $20,100,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Marker Therapeutics has 9 employees across 5 departments.
Departments
Number of employees
Funding Data
Explore Marker Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Marker Therapeutics Tech Stack
Discover the technologies and tools that power Marker Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Form builders
JavaScript frameworks
JavaScript libraries
Caching
Analytics
JavaScript libraries
Web servers
JavaScript libraries
Webmail
Programming languages
Blogs
Analytics
United Kingdom
Canada
Germany
France
Frequently asked questions
4.8
40,000 users
